Double IOP system effective in patients with macular degeneration

Article

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

Luis Amselem from the Hospital General Universitario, Valencia, Spain and colleagues evaluated the efficacy of a standard double IOP system in patients with low vision and central scotoma due to macular degeneration. The interventional, prospective, non-comparative case series included 13 consecutive surgical procedures in 10 patients.

At 12-months follow-up the difference between pre- and postoperative BCVA, refraction, position of IOLs, endothelial cell density and occurrences of postoperative complications were evaluated.

At 12-months, mean BCVA was 0.68 logMAR compared with 1.37 logMAR preoperatively. Mean best corrected clinical gain was 44%.

No statistically significant difference between the clinically evaluated and theoretically calculated residual refractions was recorded and there were no intraoperative or postoperative complications.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.